Big pharma interest remains, but the mood is fast turning gloomy.
ApexOnco Front Page
Recent articles
The Rosetta Breast-01 phase 3 trial will only evaluate patients with low PD-L1 expression.
The group’s B7-H4-targeting bispecific is out, in favour of Seagen’s ADC.
The company’s move could be a warning for rivals including GSK, AstraZeneca and Incyte.
Komet-007 showed no differentiation syndrome, but the group didn’t disclose data on menin inhibitor-experienced patients.
Will a TIGIT refocus see the stars finally align for the partners?
The biotech surges on data with its new oncology lead, so could it have a new Padcev on its hands?
Merck adds an overall survival benefit while Bristol sinks further.